StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report issued on Wednesday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Trading Down 18.8 % NAVB opened at $0.26 on Wednesday. Navidea Biopharmaceuticals has a 12-month low of $0.16 and a 12-month high of $1.24. The […]
StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.30 on Tuesday. Navidea Biopharmaceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $1.24. […]
Equities researchers at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock. Shares of NAVB stock opened at $0.69 on Friday. The firm has a 50 day moving average of $0.81. Navidea […]
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) and Heska (NASDAQ:HSKA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 5.6% of Navidea Biopharmaceuticals shares are […]
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) and VolitionRx (NYSE:VNRX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings. Profitability This table compares Navidea Biopharmaceuticals and VolitionRx’s net margins, […]